Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Chemoprevention and Biological Therapies

Abstract B61: Paving the way to Personalized Medicine: Diagnosis, prevention and treatment of early stage bone metastatic disease in prostate cancer patients with Theragnostic Radiopharmaceuticals.

Suresh C. Srivastava
Suresh C. Srivastava
Brookhaven National Laboratory, Upton, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1940-6207.PREV-12-B61 Published November 2012
  • Article
  • Info & Metrics
Loading

Abstract

A major advantage of radionuclides is that they emit radiation of different radiobiological effectiveness and range of action. This presentation will introduce a relatively novel paradigm that involves specific individual radionuclides or radionuclide pairs that have emissions that allow pre-therapy low-dose imaging plus higher-dose therapy in the same patient. We have made an attempt to sort out and organize a number of such theragnostic radionuclides and radionuclide pairs that may potentially bring us closer to the age-long dream of personalized medicine for performing tailored low-dose molecular imaging (SPECT/CT or PET/CT) to provide the necessary pre-therapy information on biodistribution, dosimetry, the dose limiting critical organ or tissue, and the maximum tolerated dose (MTD), etc. If the imaging results then warrant it, it would be possible to perform dose ranging studies and higher-dose targeted molecular therapy in in the same patient with the same radiopharmaceutical.

Tin-117m (T1/2 14.0 d; γ 159 keV, 86%) is an ideal radionuclide for the development of theragnostic radiopharmaceuticals. In contrast to most other therapeutic beta emitters, Sn-117m decays via isomeric transition with the emission of monoenergetic conversion electrons (127, 129, and 152 keV; abundance 65, 12, and 26% respectively). These emissions have short discrete ranges of between 0.22 and 0.29 mm in tissue and they deposit an intense radiation dose only within this short range in the the selectively targeted area and causing much reduced dose to radiation sensitive bone marrow and other normal organs. Moreover, its 159 keV γ-photon is perfect for pre-therapy imaging in the same patient. We have shown Sn-117m to be effective for therapy of cancer and other inflammatory conditions (e.g., atherosclerotic disease). The results of the Phase II clinical trial of tin-117m DTPA for metastaic bone pain palliation (using reactor-produced tin-117m, with specific activity ranging between 8-20 Ci/g of tin) will be presented. NCA (no-carrier-added) tin-117m is also being developed and tested for the prevention/therapy of early stage bone metastases in prostate cancer patients and for use in radioimmunotherapy. A phase II/III clinical trial for the imaging and treatment of bone metastases in prostate cancer patients is in the planning stage for 2013.

A brief description of the recently developed new or modified methods at BNL for the production and radiochemistry of a number of other potential theragnostic radionuclides, whose nuclear, physical, and chemical characteristics seem to show great promise for personalized cancer therapy will be provided.

Work at BNL supported by the U.S. Department of Energy under Contract # DE-AC02-98CH10886.

Citation Format: Suresh C. Srivastava. Paving the way to personalized medicine: Diagnosis, prevention, and treatment of early-stage bone metastatic disease in prostate cancer patients with theranostic radiopharmaceuticals. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr B61.

Note: This abstract was not presented at the conference.

  • ©2012 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Prevention Research: 5 (11 Supplement)
November 2012
Volume 5, Issue 11 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract B61: Paving the way to Personalized Medicine: Diagnosis, prevention and treatment of early stage bone metastatic disease in prostate cancer patients with Theragnostic Radiopharmaceuticals.
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract B61: Paving the way to Personalized Medicine: Diagnosis, prevention and treatment of early stage bone metastatic disease in prostate cancer patients with Theragnostic Radiopharmaceuticals.
Suresh C. Srivastava
Cancer Prev Res November 1 2012 (5) (11 Supplement) B61; DOI: 10.1158/1940-6207.PREV-12-B61

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract B61: Paving the way to Personalized Medicine: Diagnosis, prevention and treatment of early stage bone metastatic disease in prostate cancer patients with Theragnostic Radiopharmaceuticals.
Suresh C. Srivastava
Cancer Prev Res November 1 2012 (5) (11 Supplement) B61; DOI: 10.1158/1940-6207.PREV-12-B61
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Chemoprevention and Biological Therapies

  • Abstract PR13: Circadian/melatonin disruption by dim light at night drive chemotherapy resistance in breast cancer
  • Abstract PR09: Intermittent dosing regimens maintain efficacy of several cancer preventing drugs
  • Abstract PR03: Targeting multiple cell cycle regulatory points for the prevention of triple-negative breast cancer
Show more Chemoprevention and Biological Therapies

New Molecular Targets/Mechanisms of Drug Action

  • Abstract PR-01: Properties of adenomas in subjects treated with difluoromethylornithine and sulindac for reduction of colorectal adenomas
  • Abstract B85: Role of the TASK2 in regulating breast cancer cell proliferation
  • Abstract B106: Inhibition of IKKb and NFκB signaling by a novel curcumin analogue
Show more New Molecular Targets/Mechanisms of Drug Action

New Molecular Targets/Mechanisms of Drug Action: Poster Presentations - Proffered Abstracts

  • Abstract PR-01: Properties of adenomas in subjects treated with difluoromethylornithine and sulindac for reduction of colorectal adenomas
  • Abstract B85: Role of the TASK2 in regulating breast cancer cell proliferation
  • Abstract B106: Inhibition of IKKb and NFκB signaling by a novel curcumin analogue
Show more New Molecular Targets/Mechanisms of Drug Action: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement